Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin - PubMed (original) (raw)
doi: 10.1016/j.ccr.2006.07.003.
Keren Ziv, Donnette Dabydeen, Godfred Eyiah-Mensah, Marcela Riveros, Carole Perruzzi, Jingfang Sun, Rita A Monahan-Earley, Ichiro Shiojima, Janice A Nagy, Michelle I Lin, Kenneth Walsh, Ann M Dvorak, David M Briscoe, Michal Neeman, William C Sessa, Harold F Dvorak, Laura E Benjamin
Affiliations
- PMID: 16904613
- PMCID: PMC2531257
- DOI: 10.1016/j.ccr.2006.07.003
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Thuy L Phung et al. Cancer Cell. 2006 Aug.
Abstract
Endothelial cells in growing tumors express activated Akt, which when modeled by transgenic endothelial expression of myrAkt1 was sufficient to recapitulate the abnormal structural and functional features of tumor blood vessels in nontumor tissues. Sustained endothelial Akt activation caused increased blood vessel size and generalized edema from chronic vascular permeability, while acute permeability in response to VEGF-A was unaffected. These changes were reversible, demonstrating an ongoing requirement for Akt signaling for the maintenance of these phenotypes. Furthermore, rapamycin inhibited endothelial Akt signaling, vascular changes from myrAkt1, tumor growth, and tumor vascular permeability. Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor.
Figures
Figure 1. Akt activation in tumor vessels
A–D: VEGF-A-expressing rat C6 glioma cells grown subcutaneously in Nu/Nu mice were double stained with TRITC-lectin (A, red) to label blood vessels and anti-phosphorylated Akt antibody (B, green). Merged images are shown in C, with arrows indicating endothelial cell nuclei positive for phosphorylated Akt. Phosphorylated Akt is also seen in tumor cells. A higher magnification of the blood vessels within the boxed area is shown in D.
Figure 2. Pathological blood vessel formation in double transgenic myrAkt1 mice
A: VE-Cadherin:†TA line drives expression of TET:lacZ reporter gene in adult vasculature as shown by histology of the skin expressing β-galactosidase activity (blue stain) in endothelial cells. B–E: Whole tissue view of the flank skin of wild-type (WT) mice (B) and double transgenic (DT) littermates (C). Corresponding histology sections of wild-type (D) and double transgenic (E) skin taken at the same magnification showing enlarged vessels in double transgenic skin. Cutaneous edema separating dermal collagen is shown (E, arrow). Note the increase in thickness of double transgenic dermis from edema as indicated by a bar on the left side of each panel. F and G: One micrometer sections of blood vessels in wild-type (F) and double transgenic (G) mice. MyrAkt1 expression induced enlarged vessels with elongated endothelial cells and transluminal bridges (arrow). H and I: Skin sections from wild-type (H) and double transgenic mice (I) were analyzed for the presence of smooth muscle cells/pericytes by double immunofluorescent staining with anti-SMA antibody (red) and BS-1 lectin (green), which labels endothelial cells. Arrow in I shows enlarged vessel with deficient SMA staining. J–M: Increased levels of activated Akt in the vasculature in double transgenic myrAkt1 mice. Wild-type skin stained with FITC-lectin (J, green) to label blood vessels, and anti-phosphorylated Akt antibody (K, red). The same magnification of myrAkt1 double transgenic skin labeled with FITC-lectin (L, green) and anti-phosphorylated Akt antibody (M, red).
Figure 3. MRI studies of the effects of endothelial myrAkt1 on blood volume and vascular permeability
A: Mice were taken off tetracycline for 7 days, then imaged by dynamic contrast enhanced MRI using intravenously administered biotin-BSA-Gd-DTPA. The intravascular distribution of contrast agent in vivo is seen in overlay of maximal intensity projections maps from images that were taken prior to contrast injection (gray) and immediately after contrast injection (color). B: Total blood volume was significantly higher in myrAkt1 double transgenic mice than in control mice (p = 0.007; n = 6 mice per group). C: Significant changes in blood volume fraction (fBV) were observed in the brain and hindlimb of double transgenicmice as compared to control mice (brain, p = 0.005; hindlimb, p = 0.003; n = 6 mice per group). D: Increased permeability surface area product (PS) was observed in the brain, limb, liver, and kidney, with statistically significant differences seen in the liver (p = 0.01; n = 6 mice per group). E and F: Edema is seen in skeletal muscles in double transgenic mice as shown by separation of muscle fibers in these mice (F) as compared to controlmice (E). Bars in graphs represent means ± standard deviations.
Figure 4. Sustained endothelial Akt activation leads to structural and functional changes
A and B: Vascular permeability was assessed in wild-type (WT) and double transgenic (DT) littermates. Confocal microscopic images of skin from wild-type (A) and double transgenic (B) mice after FITC-dextran perfusion for 2 hr. Arrows indicate extravasated FITC-dextran into the interstitial space. C–F: Lymphatic structure and function were assessed in control and double transgenic animals. Lymphatic function was demonstrated by Evans blue dye extravasation and lymphatic uptake in wild-type (C) and double transgenic (D)mesentery. Inset in D shows higher magnification of mesenteric lymphatic (blue, arrow)and adjacent blood vessels (red). Intralymphatic injection of colloidal carbon (India ink) in the mouse ear highlights normal lymphatic network (white arrows) in the ear skin in both wild-type (E) and double transgenic (F) mice. The blood vessels in double transgenic mice are enlarged compared to the normal vascular pattern in control mice (black arrows). G and H: Electron microscopic studies of double transgenic endothelial cells demonstrate intact and closed intercellular junctions (G, arrows) and many VVOs (H, arrows).
Figure 5. Baseline vascular permeability is increased in double transgenic myrAkt1 mice but not in Akt1 null mice
A–C: Wild-type (WT) and double transgenic (DT) mice were taken off tetracycline for 5 days prior to analysis of baseline permeability. Evans blue dye (50 mg/kg) was injected i.v. and allowed to circulate for 8 hr, at which time the animals were sacrificed and various organs were collected for analysis. Relatively normal skin vasculature in wild-type and double transgenic mice is shown in A. Evans blue dye was extracted from various organs, and the amount of extracted dye was measured by spectrophotometric absorbance at 620 nm (B). Lungs from WT and DT mice 8 hr after Evans blue injection (C). D and E: Miles assay in WT and DT mice that were off tetracycline for 5 days. Evans blue dye was injected in the tail vein. Saline or VEGF-A was immediately injected intradermally in the back skin (D). Quantification of Evans blue dye extracted from the skin (E). F–H: Baseline vascular permeability in Akt1−/− mice and control littermates was determined as described in A. F: Whole lungs taken from Akt1+/+ and _Akt1_−/− mice 8 hr after Evans blue injection. G: Quantitation of extravasated Evans blue in various organs from Akt1+/+, Akt1+/−, and Akt1−/− mice. H: Normal vasculature is seen in the flank skin in these mice. Data from all the experiments above represented four mice per group and were calculated as micrograms of dye per gram tissue weight (mean ± SEM). p value < 0.05 was considered statistically significant. NS is not statistically significant.
Figure 6. Reversibility of the vascular phenotype in double transgenic myrAkt1 mice
A–D: The same double transgenic mouse was followed over a time course of tetracycline administration. Images of the whole body and ear are shown for the mouse raised to maturity on tetracycline (A), followed by tetracycline withdrawal for 7 weeks (B), then back on tetracycline for 6 days (C) and 4 weeks (D). E–G: The normal cutaneous vasculature in similarly treated representative double transgenic mice (E) was dramatically altered in response to tetracycline withdrawal (F). Restoration of a near-normal vascular pattern was observed when these animals were placed back on tetracycline for 4 weeks (G).
Figure 7. Effects of rapamycin on pathological vessel formation in double transgenic myrAkt1 mice
A–C: Effects of rapamycin on VEGF-A-induced vascular permeability. Athymic Nu/Nu mice were pretreated with either solvent (A) or rapamycin (4 mg/kg, intraperitoneal) (B) for 24 hr prior to intravenous injection of Evans blue dye. Immediately following Evans blue injection, saline or VEGF-A was injected intradermally in the ears and back skin. Photographs of extravasated Evans blue in the ears of treated animals are shown. Quantitation of Evans blue dye extracted from the ears and skin (C). Data represent five to six mice per rapamycin- or solvent-treated group, three sites per saline or VEGF-A treatment, and were calculated as micrograms of dye per gram tissue weight (mean ± SEM). p value < 0.05 was considered statistically significant. NS, not statistically significant. D–I: Wild-type (WT) and double transgenic (DT) littermates were taken off tetracycline to induce myrAkt1 expression. Starting on the same day, they were given daily intraperitoneal injections of rapamycin or solvent for 7 days. On day 8, the mice were perfused intravenously with FITC-dextran for 60 min, and the flank skin was examined (D–F) (whole tissue view, magnification ×2.5) and harvested for confocal microscopy (G–I) (magnification x200). Extravasation of FITC-dextran from the blood vessels in solvent-treated DT mice is shown in H (arrows). J: Double transgenic endothelial cells were treated for 48 hr ± tetracycline ± rapamycin and analyzed by Western blot for phosphorylated Akt and expression of HA-tagged myrAkt1 transgene. K: Control (C) and double transgenic myrAkt1 mice were taken off tetracycline and starting on the same day injected intraperitoneally with rapamycin for 4 days. The animals were sacrificed and the kidneys were harvested and analyzed by Western blot for phosphorylated and total Akt. L: Primary human dermal microvascular endothelial cells were treated with rapamycin (1–50 ng/ml) for 3 days and analyzed by Western blot for phosphorylated and total Akt. M: Inbred FVBmice were injected intraperitoneally with rapamycin (0.1–4 mg/kg/day) for 4 days. The animals were sacrificed, and the kidneys were harvested and analyzed by Western blot.
Figure 8. Effects of rapamycin on C6 rat glioma tumor
A: Athymic Nu/Nu mice were injected subcutaneously with C6 rat glioma cells expressing VEGF-A. Tumors were allowed to grow to ~0.1 cm3 before randomization into solvent or rapamycin (4 mg/kg/day) treatment group. Tumor size was measured every 2–3 days with a caliper. Tumor growth is presented as the mean ± SD, n = 4 mice per treatment group, two tumor sites per mouse. p values were obtained by comparison with solvent-treated group. B: The mice in A were injected with Evans blue dye (50 mg/kg, i.v.) and allowed to circulate for 30 min before perfusion with 100 cc of saline to clear intravascular Evans blue. Tumors were resected and Evans blue content was quantified (n = 4 mice per treatment group). p values were obtained by comparison with solvent-treated group. C: Nu/Nu mice bearing C6 tumors were treated ± rapamycin (0.5 or 1.0 mg/kg/day) for 8 days. Tumors were harvested for Western blot analysis of phosphorylated and total S6 kinase and Akt. D and E: Frozen sections of C6 tumors from C were immunostained for phosphorylated Akt (red) and CD31 (green) to label blood vessels. Nuclei were counterstained with Hoechst dye (blue). Arrows indicate endothelial cell nuclei positive for phosphorylated Akt in solvent-treated tumors (D) and loss of phosphorylated Akt in endothelial cells in rapamycin-treated tumors (E). Magnification x200.
Comment in
- Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
Stoeltzing O, Meric-Bernstam F, Ellis LM. Stoeltzing O, et al. Cancer Cell. 2006 Aug;10(2):89-91. doi: 10.1016/j.ccr.2006.07.013. Cancer Cell. 2006. PMID: 16904605 Review.
Similar articles
- Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
Stoeltzing O, Meric-Bernstam F, Ellis LM. Stoeltzing O, et al. Cancer Cell. 2006 Aug;10(2):89-91. doi: 10.1016/j.ccr.2006.07.013. Cancer Cell. 2006. PMID: 16904605 Review. - Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression.
Phung TL, Eyiah-Mensah G, O'Donnell RK, Bieniek R, Shechter S, Walsh K, Kuperwasser C, Benjamin LE. Phung TL, et al. Cancer Res. 2007 Jun 1;67(11):5070-5. doi: 10.1158/0008-5472.CAN-06-3341. Cancer Res. 2007. PMID: 17545582 Free PMC article. - Endothelial, but not smooth muscle, peroxisome proliferator-activated receptor β/δ regulates vascular permeability and anaphylaxis.
Wawrzyniak M, Pich C, Gross B, Schütz F, Fleury S, Quemener S, Sgandurra M, Bouchaert E, Moret C, Mury L, Rommens C, Mottaz H, Dombrowicz D, Michalik L. Wawrzyniak M, et al. J Allergy Clin Immunol. 2015 Jun;135(6):1625-35.e5. doi: 10.1016/j.jaci.2014.11.006. Epub 2014 Dec 31. J Allergy Clin Immunol. 2015. PMID: 25556996 - Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Amin DN, et al. Microvasc Res. 2008 May;76(1):15-22. doi: 10.1016/j.mvr.2008.01.002. Epub 2008 Mar 18. Microvasc Res. 2008. PMID: 18440031 - Endothelial caveolin and its scaffolding domain in cancer.
Bernatchez P. Bernatchez P. Cancer Metastasis Rev. 2020 Jun;39(2):471-483. doi: 10.1007/s10555-020-09895-6. Cancer Metastasis Rev. 2020. PMID: 32472243 Review.
Cited by
- Natural Products in the Treatment of Retinopathy of Prematurity: Exploring Therapeutic Potentials.
Heo JI, Ryu J. Heo JI, et al. Int J Mol Sci. 2024 Aug 2;25(15):8461. doi: 10.3390/ijms25158461. Int J Mol Sci. 2024. PMID: 39126030 Free PMC article. Review. - Akt is a mediator of artery specification during zebrafish development.
Zhou W, Ghersi JJ, Ristori E, Semanchik N, Prendergast A, Zhang R, Carneiro P, Baldissera G, Sessa WC, Nicoli S. Zhou W, et al. Development. 2024 Sep 1;151(17):dev202727. doi: 10.1242/dev.202727. Epub 2024 Sep 2. Development. 2024. PMID: 39101673 Free PMC article. - Available Therapeutic Options for Corneal Neovascularization: A Review.
Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D. Drzyzga Ł, et al. Int J Mol Sci. 2024 May 17;25(10):5479. doi: 10.3390/ijms25105479. Int J Mol Sci. 2024. PMID: 38791518 Free PMC article. Review. - Transforming growth factor-β receptors: versatile mechanisms of ligand activation.
Chia ZJ, Cao YN, Little PJ, Kamato D. Chia ZJ, et al. Acta Pharmacol Sin. 2024 Jul;45(7):1337-1348. doi: 10.1038/s41401-024-01235-6. Epub 2024 Feb 13. Acta Pharmacol Sin. 2024. PMID: 38351317 Free PMC article. Review. - Anti-angiogenesis in colorectal cancer therapy.
Yang Z, Zhang X, Bai X, Xi X, Liu W, Zhong W. Yang Z, et al. Cancer Sci. 2024 Mar;115(3):734-751. doi: 10.1111/cas.16063. Epub 2024 Jan 17. Cancer Sci. 2024. PMID: 38233340 Free PMC article. Review.
References
- Baluk P, McDonald DM. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am. J. Physiol. 1994;266:L461–L468. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL071049/HL/NHLBI NIH HHS/United States
- T32 HL07893/HL/NHLBI NIH HHS/United States
- CA106263/CA/NCI NIH HHS/United States
- R01 CA106263-04/CA/NCI NIH HHS/United States
- P01 CA092644/CA/NCI NIH HHS/United States
- P01 CA09264401/CA/NCI NIH HHS/United States
- R01 CA106263/CA/NCI NIH HHS/United States
- R01 CA109086/CA/NCI NIH HHS/United States
- R01 HL71049-01/HL/NHLBI NIH HHS/United States
- T32 HL007893/HL/NHLBI NIH HHS/United States
- R01 CA109086-04/CA/NCI NIH HHS/United States
- P01 AI50157/AI/NIAID NIH HHS/United States
- T32 DK007726/DK/NIDDK NIH HHS/United States
- R01 AI046756/AI/NIAID NIH HHS/United States
- P01 AI050157/AI/NIAID NIH HHS/United States
- R01 CA109086-03/CA/NCI NIH HHS/United States
- P01 CA092644-04/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases